Skip to main content

Advertisement

SpringerLink
Log in

Assessment of vaginal atrophy: a review

  • Review Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

The aim of this study is to provide an evidence-based definition of vaginal atrophy (VA) and present an overview of subjective and objective measurements of VA applicable in clinical practice and research.

Methods

A systematic literature search was performed in MEDLINE and EMBASE to identify studies reporting on measurement properties of diagnostic instruments for VA. Additional searches in MEDLINE aimed to document the definitions, diagnostic criteria, and outcome measures of VA. Studies reporting on definitions, diagnosis, outcome measurements, and measurement properties of diagnostic instruments of VA were selected.

Results

Specific symptoms for VA that were consistently described could be identified to suggest an evidence-based definition of VA. As subjective outcome measurements, seven scoring systems to assess the signs of VA during physical examination were identified. The most bothersome symptom (MBS) approach is most useful in clinical practice and research as it focuses on the most common symptoms of VA. As objective outcome measurements, numerous ways to assess vaginal cytology and vaginal pH were identified.

Conclusions

At the moment, there is no consensus on the definition and assessment of VA. We propose to define VA as a common manifestation of estrogen decline associated with specific symptoms of which the most common are: vaginal dryness, itching or irritation, and dyspareunia. In both clinical and research settings, subjective assessment (the MBS approach) and objective assessments of VA (measurement of vaginal maturation index and vaginal pH) should be combined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61(10):3090–3096

    CAS  PubMed  Google Scholar 

  2. Levine KB, Williams RE, Hartmann KE (2008) Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 15(4 Pt 1):661–666

    Article  PubMed  Google Scholar 

  3. Nappi RE, Kokot-Kierepa M (2010) Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 67(3):233–238

    Article  PubMed  Google Scholar 

  4. Santoro N, Komi J (2009) Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 6(8):2133–2142

    Article  PubMed  Google Scholar 

  5. Stika CS (2010) Atrophic vaginitis. Dermatol Ther 23(5):514–522

    Article  PubMed  Google Scholar 

  6. Sturdee DW, Panay N, International Menopause Society Writing Group (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13(6):509–522

  7. Archer DF (2010) Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 17(1):194–203

  8. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry (2003) Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms—recommendations for clinical evaluation

  9. US Department of Health an Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry (2006) Patient-reported outcome measures: use in medical product development to support labeling claims

  10. Terwee CB, Jansma EP, Riphagen II, de Vet HC (2009) Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments. Qual Life Res 18(8):1115–1123

    Article  PubMed Central  PubMed  Google Scholar 

  11. Chollet JA, Carter G, Meyn LA, Mermelstein F, Balk JL (2009) Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. Menopause 16(5):978–983

    Article  PubMed  Google Scholar 

  12. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD (2005) Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52(Suppl 1):S46–S52

  13. Brenner PF (1988) The menopausal syndrome. Obstet Gynecol 72(5 Suppl):6S–11S

    CAS  PubMed  Google Scholar 

  14. Nyirjesy P, Leigh RD, Mathew L, Lev-Sagie A, Culhane JF (2012) Chronic vulvovaginitis in women older than 50 years: analysis of a prospective database. J Low Genit Tract Dis 16(1):24–29

  15. Greendale GA, Zibecchi L, Petersen L, Ouslander JG, Kahn B, Ganz PA (1999) Development and validation of a physical examination scale to assess vaginal atrophy and inflammation. Climacteric 2(3):197–204

    Article  CAS  PubMed  Google Scholar 

  16. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M (2008) Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 111(1):67–76

    Article  CAS  PubMed  Google Scholar 

  17. Karaosmanoglu O, Cogendez E, Sozen H, Asoglu MR, Akdemir Y, Eren S (2011) Hyaluronic acid in the treatment of postmenopausal women with atrophic vaginitis. Int J Gynaecol Obstet 113(2):156–157

    Article  PubMed  Google Scholar 

  18. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS (2000) 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7(3):156–161

    Article  CAS  PubMed  Google Scholar 

  19. Lynch C (2009) Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health (Larchmt) 18(10):1595–1606

  20. Crothers BA, Booth CN, Darragh TM, Means MM, Souers RJ, Thomas N, Moriarty AT (2012) Atrophic vaginitis: concordance and interpretation of slides in the College of American Pathologists Cervicovaginal Interlaboratory Comparison Program in Gynecologic Cytopathology. Arch Pathol Lab Med 136(11):1332–1338

    Article  PubMed  Google Scholar 

  21. Capewell AE, McIntyre MA, Elton RA (1992) Post-menopausal atrophy in elderly women: is a vaginal smear necessary for diagnosis? Age Ageing 21(2):117–120

    Article  CAS  PubMed  Google Scholar 

  22. Yildirim B, Kaleli B, Düzcan E, Topuz O (2004) The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas 49(4):334–337

    Article  CAS  PubMed  Google Scholar 

  23. Hummelen R, Macklaim JM, Bisanz JE, Hammond JA, McMillan A, Vongsa R, Koenig D, Gloor GB, Reid G (2011) Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One 6(11):e26602

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F (2005) Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 50(2):98–104

    Article  CAS  PubMed  Google Scholar 

  25. Bachmann GA, Komi JO, Ospemifene Study Group (2010) Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 17(3):480–486

    PubMed  Google Scholar 

  26. Bygdeman M, Swahn ML (1996) Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23(3):259–263

    Article  CAS  PubMed  Google Scholar 

  27. Manonai J, Chittacharoen A, Theppisai U, Theppisai H (2007) Effect of Pueraria mirifica on vaginal health. Menopause 14(5):919–924

    Article  PubMed  Google Scholar 

  28. Simunić V, Banović I, Ciglar S, Jeren L, Pavicić Baldani D, Sprem M (2003) Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 82(2):187–197

    Article  PubMed  Google Scholar 

  29. Rane A, Hassan S, Corstiaans A (2000) Does conventional HRT protect from urogenital atrophy? A prospective study. J Obstet Gynaecol 20(3):306–307

    Article  CAS  PubMed  Google Scholar 

  30. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH (2010) A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 17(2):281–289

    Article  PubMed  Google Scholar 

  31. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W (2008) Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. [Erratum appears in Obstet Gynecol 2008 Dec;112(6):1392]. Obstet Gynecol 112(5):1053–1060

  32. Chollet JA (2011) Efficacy and safety of ultra-low-dose Vagifem (10 mcg). Patient Prefer Adherence 5:571–574

    Article  PubMed Central  PubMed  Google Scholar 

  33. Le Donne M, Caruso C, Mancuso A, Costa G, Iemmo R, Pizzimenti G, Cavallari V (2011) The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet 283(6):1319–1323

    Article  CAS  PubMed  Google Scholar 

  34. Al-Baghdadi O, Ewies AA (2009) Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 12(2):91–105

  35. Cano A, Estévez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL, Castellanos E, Moral E, Nieto C, del Prado JM, Ferrer J (2012) The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005 % estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 19(10):1130–1139

  36. Minkin MJ, Maamari R, Reiter S (2013) Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Womens Health 5:133–139

    Article  PubMed Central  PubMed  Google Scholar 

  37. Pandit L, Ouslander JG (1997) Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 314(4):228–231

  38. van der Laak JA, Schijf CP, Kerstens HM, Heijnen-Wijnen TH, de Wilde PC, Hanselaar GJ (1999) Development and validation of a computerized cytomorphometric method to assess the maturation of vaginal epithelial cells. Cytometry 35(3):196–202

    Article  PubMed  Google Scholar 

  39. McEndree B (1999) Clinical application of the vaginal maturation index. Nurse Pract 24(9):48–56

  40. Simon JA, Reape KZ, Wininger S, Hait H (2008) Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil Steril 90(4):1132–1138

    Article  CAS  PubMed  Google Scholar 

  41. Barentsen R, van de Weijer PH, Schram JH (1997) Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 71(1):73–80

    Article  CAS  PubMed  Google Scholar 

  42. Casper F, Petri E (1999) Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 10(3):171–176

    Article  CAS  PubMed  Google Scholar 

  43. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I (1996) A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 174(1 Pt 1):85–92

    Article  CAS  PubMed  Google Scholar 

  44. Speroff L (2003) Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 102(4):823–834

    Article  CAS  PubMed  Google Scholar 

  45. Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I (1994) A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 171(3):624–632

    Article  CAS  PubMed  Google Scholar 

  46. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, Fraser ID (1996) A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 103(4):351–358

    Article  CAS  PubMed  Google Scholar 

  47. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB (2011) Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 117(4):922–927

    Article  PubMed  Google Scholar 

  48. Zeyneloglu HB, Oktem M, Haberal NA, Esinler I, Kuscu E (2007) The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women. Fertil Steril 88(2):530–532

    Article  CAS  PubMed  Google Scholar 

  49. Speroff L, Haney AF, Gilbert RD, Ellman H, Estradiol Acetate Investigator Group (2006) Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause 13(3):442–450

  50. Utian WH, Speroff L, Ellman H, Dart C (2005) Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. Menopause 12(6):708–715

    Article  PubMed  Google Scholar 

  51. Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer I, Kivanҫ E (2011) The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet 283(3):539–543

    Article  CAS  PubMed  Google Scholar 

  52. Pinkerton JV, Shifren JL, La Valleur J, Rosen A, Roesinger M, Siddhanti S (2003) Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 10(1):45–52

    PubMed  Google Scholar 

  53. Meisels A (1967) The maturation value. Acta Cytol 11:249

    CAS  PubMed  Google Scholar 

  54. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A (2010) A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 7(3):1284–1290

    Article  CAS  PubMed  Google Scholar 

  55. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H (2009) Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 16(4):735–741

    Article  PubMed  Google Scholar 

  56. Manonai J, Songchitsomboon S, Chanda K, Hong JH, Komindr S (2006) The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial. Maturitas 54(2):135–140

    Article  CAS  PubMed  Google Scholar 

  57. Griesser H, Skonietzki S, Fischer T, Fielder K, Suesskind M (2012) Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 71(4):360–368

  58. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC (2007) Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 109(3):588–596

    Article  CAS  PubMed  Google Scholar 

  59. Davila GW, Singh A, Karapanagiotou I, Woodhouse S, Huber K, Zimberg S, Seiler J, Kopka SL (2003) Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol 188(2):382–388

    Article  PubMed  Google Scholar 

  60. Karp DR, Jean-Michel M, Johnston Y, Suciu G, Aguilar VC, Davila GW (2012) A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Med Reconstr Surg 18(4):211–215

    Article  PubMed  Google Scholar 

  61. Smith P, Heimer G, Lindskog M, Ulmsten U (1993) Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 16(2):145–154

    Article  CAS  PubMed  Google Scholar 

  62. Nilsson K, Risberg B, Heimer G (1995) The vaginal epithelium in the postmenopause–cytology, histology and pH as methods of assessment. Maturitas 21(1):51–56

    Article  CAS  PubMed  Google Scholar 

  63. Yumru AE, Bozkurt M, Inci Coşkun E, Baykan G (2009) The use of local 17beta-oestradiol treatment for improving vaginal symptoms associated with post-menopausal oestrogen deficiency. J Int Med Res 37(1):198–204

    Article  CAS  PubMed  Google Scholar 

  64. Benjamin F, Deutsch S (1980) Immunoreactive plasma estrogens and vaginal hormone cytology in postmenopausal women. Int J Gynaecol Obstet 17(6):546–550

    CAS  PubMed  Google Scholar 

  65. Bachmann G, Bouchard C, Hoppe D, Ranganath R, Altomare C, Vieweg A, Graepel J, Helzner E (2009) Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 16(4):719–727

    Article  PubMed  Google Scholar 

  66. Schaffer J, Fantl JA (1996) Urogenital effects of the menopause. Baillieres Clin Obstet Gynaecol 10(3):401–417

  67. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S (2012) Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet 285(2):397–403

    Article  PubMed  Google Scholar 

  68. Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, Marci R, Cosmi E (2004) Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 11(1):49–56

    Article  PubMed  Google Scholar 

  69. Mishell D (1987) Menopause: physiology and pharmacology. Yearbook, Chicago

    Google Scholar 

  70. Wied G, Bibbo M (1975) Evaluation of endocrinologic condition by exfoliative cytology. In: Gold JJ (ed) Textbook of gynaecologic endocrinology. Harper and Row, New York

    Google Scholar 

  71. Milsom I, Arvidsson L, Ekelund P, Molander U, Eriksson O (1993) Factors influencing vaginal cytology, pH and bacterial flora in elderly women. Acta Obstet Gynecol Scand 72(4):286–291

    Article  CAS  PubMed  Google Scholar 

  72. Caillouette J, Sharp C, Zimmerman G, Roy S (1997) Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol 176:1270–1275

    Article  CAS  PubMed  Google Scholar 

  73. Roy S, Caillouette J, Roy T, Faden J (2004) Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol 190:1272–1277

    Article  CAS  PubMed  Google Scholar 

  74. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côte I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J (2009) Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 16(5):907–922

    Article  PubMed  Google Scholar 

  75. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A (2001) The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 27(5):255–260

    Article  CAS  PubMed  Google Scholar 

  76. Bachmann GA, Schaefers M, Uddin A, Utian WH (2009) Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. Menopause 16(5):877–882

    Article  PubMed  Google Scholar 

  77. Parsons A, Merritt D, Rosen A, Heath H III, Siddhanti S, Plouffe L Jr, Study Groups on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream (2003) Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 101(2):346–352

  78. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, Ravarino N, Ponzone R, Sismondi P (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 26(6):404–412

    Article  CAS  PubMed  Google Scholar 

  79. Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côte I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J (2011) Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 14(2):282–288

    Article  CAS  PubMed  Google Scholar 

  80. Brizzolara S, Killeen J, Severino R (1999) Vaginal pH and parabasal cells in postmenopausal women. Obstet Gynecol 94:700–703

    Article  CAS  PubMed  Google Scholar 

  81. Ettinger B, Hait H, Reape KZ, Shu H (2008) Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 15(5):885–889

    Article  PubMed  Google Scholar 

  82. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côte I, Labrie C, Lavoie L, Berger L, Martel C, Balser J (2010) High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol Endocrinol 26(7):524–532

    Article  CAS  PubMed  Google Scholar 

  83. Eriksen B (1999) A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 180(5):1072–1079

    Article  CAS  PubMed  Google Scholar 

  84. Eriksen PS, Rasmussen H (1992) Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 44(2):137–144

    Article  CAS  PubMed  Google Scholar 

  85. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM (2006) Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 13(6):917–925

    Article  PubMed  Google Scholar 

  86. McKenna SP, Whalley D, Renck-Hooper U, Carlin S, Doward LC (1999) The development of a quality of life instrument for use with post-menopausal women with urogenital atrophy in the UK and Sweden. Qual Life Res 8(5):393–398

    Article  CAS  PubMed  Google Scholar 

  87. Lester J, Bernhard L, Ryan-Wenger N (2012) A self-report instrument that describes urogenital atrophy symptoms in breast cancer survivors. West J Nurs Res 34(1):72–96

    Article  PubMed  Google Scholar 

  88. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O’Neill S, Kirkegard Y, Fraser IS (2005) Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 8(1):83–92

    Article  CAS  PubMed  Google Scholar 

  89. Bachmann G (1994) Vulvo-vaginal complaints. In: Lobo R (ed.) Treatment of the postmenopausal woman. Raven, New York

  90. Raymundo N, Yu-cheng B, Zi-yan H, Lai CH, Leung K, Subramaniam R, Bin-rong C, Ling YS, Nasri N, Calimon N (2004) Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women. Climacteric 7(3):312–318

    Article  CAS  PubMed  Google Scholar 

  91. Laan E, van Lunsen RH (1997) Hormones and sexuality in postmenopausal women: a psychophysiological study. J Psychosom Obstet Gynaecol 18(2):126–133

    Article  CAS  PubMed  Google Scholar 

  92. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L (1983) Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 249(16):2195–2198

    Article  CAS  PubMed  Google Scholar 

  93. Nappi RE, Kokot-Kierepa M (2012) Vaginal health: insights, views & attitudes (VIVA) - results from an international survey. Climacteric 15(1):36–44

    Article  CAS  PubMed  Google Scholar 

  94. van Geelen JM, van de Weijer PH, Arnolds HT (2000) Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years. Int Urogynecol J Pelvic Floor Dysfunct 11(1):9–14

    Article  PubMed  Google Scholar 

  95. Pastore LM, Carter RA, Hulka BS, Wells E (2004) Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas 49(4):292–303

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Academic Medical Center, H4.232, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands

    M. A. Weber & J. P. W. R. Roovers

  2. Medical Library, Academic Medical Center, Amsterdam, The Netherlands

    J. Limpens

Authors
  1. M. A. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Limpens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. P. W. R. Roovers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. A. Weber.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Table 3

(DOC 243 kb)

Appendix 1

Appendix 1

Appendix 1 Database (s): Ovid MEDLINE (R) in-process & other non-indexed citations and Ovid MEDLINE (R) 1946 to present
Full size table

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weber, M.A., Limpens, J. & Roovers, J.P.W.R. Assessment of vaginal atrophy: a review. Int Urogynecol J 26, 15–28 (2015). https://doi.org/10.1007/s00192-014-2464-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-014-2464-0

Keywords

Search

Navigation